Product Information
BioNK
BioNK is our corporation’s proprietary NK cell formulation aimed on shaping the future of advanced cellular therapies for those who need.
BioNK-c Pipeline
- BioNK cell formulations
- BioNK combinatory protocols
- CAR-BioNK
Key aspects of BioNK-c cell therapy products include
- Allogeneic NK Cell Therapy: BioNK cell formulations are sourced from cord blood and are to be clinically tested to be administered to patients as an off-the-shelf therapeutic product. Allogeneic BioNK cell therapy offers the advantage of immediate availability and can be used to treat a wide range of cancers.
- Engineering and Expansion: BioNK-c is developing protocols to enhance the efficacy of NK cell therapy through genetic engineering and ex vivo expansion. These approaches aim to augment NK cell function, improve persistence, and enhance tumor targeting capabilities.
- Combination Therapies: BioNK-c pipeline includes the use of its BioNK cells in combination with other treatments, such as monoclonal antibodies or checkpoint inhibitors, to enhance therapeutic efficacy. Combinatorial approaches leverage the complementary mechanisms of action of different therapies to achieve synergistic anti-tumor effects.
- Immunomodulatory Properties: BioNK-c is exploring the fact that NK cells possess immunomodulatory properties that extend beyond direct cytotoxicity. They can regulate the activity of other immune cells, such as T cells and dendritic cells, and modulate the tumor microenvironment to promote anti-tumor immune responses.
- Clinical Applications: BioNK-c pipeline aims on the treatment of various hematologic malignancies, including acute myeloid leukemia (AML), lymphoma, and multiple myeloma, as well as solid tumors such as ovarian cancer and melanoma. Clinical trials are expected to start by 2025 to evaluate the safety and efficacy of BioNK across a range of cancer types.